New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...

Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclusive global license and collaboration ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

The data, which will be presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, builds upon earlier results presented at ASCO. The study showed a disease control rate of 93.8% at the ...

VS-7375 is a potential best-in-class, potent, and selective oral KRAS G12D dual ON/OFF inhibitor. VS-7375 is the lead program from the Verastem Oncology discovery, development, and ...

Bayer & Kumquat Biosciences enter global license and collaboration to develop and commercialize Kumquat’s KRAS G12D inhibitor: Berlin, Germany Wednesday, August 13, 2025, 11:00 ...

Zoldonrasib, a RAS (ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small ...